With only a week to go before the Nov. 8, 2022 midterm election in the U.S., speculation is growing over what the 118th Congress will look like and what it will mean for the biopharma and med-tech industries. If Republicans flip either chamber, it would prevent either party from using the reconciliation process, which requires the barest majority in the Senate, to pass legislation such as the Inflation Reduction Act with its provisions giving the federal government some control over prescription drug prices. Read More
In relapsed/refractory acute myeloid leukemia (AML), an indication that still needs adequate standard-of-care therapy, Actinium Pharmaceuticals Inc.’s topline pivotal phase III data shone brightly with radiotherapy lead candidate Iomab-B. Read More
Heading into the readout of the phase III Mont Blanc study testing Nicox SA’s NCX-470, a nitric oxide-donating version of prostaglandin analogue bimatoprost, analysts were looking for a superior intraocular pressure-lowering profile vs. latanoprost, predicting such data could position the drug as a new standard of care in a crowded market. Read More
Shares in Inventiva SA (Paris:IVAA) fell about 18% after development partner Abbvie Inc. quit development of the inflammatory disease drug cedirogant following an unfavorable readout from a phase II toxicology study. The companies had worked on the asset together for about a decade. Inventiva emerged from Abbott in 2012, before the healthcare giant split in 2013 to form pharma specialist Abbvie and Abbott Laboratories, focused on medical devices. Read More
JW Therapeutics Co. Ltd. has formed a partnership with 2seventy Bio Inc. to launch a translational and clinical cell therapy development program for the development of T cell-based immunotherapies in mainland China, Hong Kong and Macao. Read More
Clinical updates, including trial initiations, enrollment status and data readouts and publications: Edgewise, Morphosys, Nuvalent, Quantum Genomics, Sanofi, Sciwind, Urovant Sciences, Vyluma. Read More
Biopharma happenings, including deals and partnerships, grants, preclinical data and other news in brief: Aim, Coeptis, Cytosorbents, Epivax, Intravacc, Intrinsix. Read More
Regulatory snapshots, including global drug submissions and approvals, clinical trial approvals and other regulatory decisions and designations: Abbvie, Almirall, Eli Lilly, Fosun Kite, Genmab, Gilead Sciences, Jiangsu Recbio Technology, Kite, Outlook, Pharming. Read More